Lv1
40 积分 2024-08-07 加入
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma
12天前
已完结
A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma
1个月前
已完结
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial
2个月前
已关闭
Non-Hodgkin's Lymphoma in Couples
2个月前
已完结
Markers of Response for the Antiangiogenic Agent Bevacizumab
2个月前
已完结
Targeted therapies for cutaneous T-cell lymphomas
4个月前
已关闭
Targeted therapies for cutaneous T-cell lymphomas
4个月前
已关闭
Therapeutic advances for Cutaneous T Cell Lymphoma
4个月前
已完结
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma
4个月前
已完结
皖公网安备34019202002308
